Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The Cigna Group exceeded analyst expectations in revenue and earnings, fueled by ongoing growth across its varied portfolio of companies.</li><li>Cigna produced total revenues of $48.6 billion, adjusted earnings per share of $6.13, and cash flow from operations of $2.5 billion in the quarter.</li><li>Another strong quarter was experienced by the company's market-leading pharmacy, care, and benefits portfolio at Evernorth Health Services.</li></ul>

The Cigna Group exceeded analyst expectations in revenue and earnings, fueled by ongoing growth across its varied portfolio of companies.Cigna produced total revenues of $48.6 billion, adjusted earnings per share of $6.13, and cash flow from operations of $2.5 billion in the quarter.Another strong quarter was experienced by the company's market-leading pharmacy, care, and benefits portfolio at Evernorth Health Services.

The Cigna Group: How Innovation & Affordability Are Driving Impressive Growth! - Major Drivers

<ul><li>The last quarter was an all-around beat for Cigna with revenues and earnings well above Wall Street expectations.</li><li>Evernorth, including pharmacy benefit services, Specialty Pharmacy, and Evernorth Care, retained, expanded, and won new relationships.</li><li>Cigna Healthcare's health benefits platform achieved revenue and customer growth, with solid performance across U.S. commercial, U.S. government, and international health businesses.</li></ul>

The last quarter was an all-around beat for Cigna with revenues and earnings well above Wall Street expectations.Evernorth, including pharmacy benefit services, Specialty Pharmacy, and Evernorth Care, retained, expanded, and won new relationships.Cigna Healthcare's health benefits platform achieved revenue and customer growth, with solid performance across U.S. commercial, U.S. government, and international health businesses.

The Cigna Group: Focus on Affordability and Pricing Drives Medical Cost Performance – Key Drivers

<ul><li>Cigna Corporation delivered a mixed performance in the last quarter with below-par revenues but an earnings beat.</li><li>Through a mix of dividends and share repurchases, Cigna returned $9 billion to shareholders.</li><li>Furthermore, in Evernorth Care Services, Cigna enhanced and expanded its care management and care delivery skills portfolio.</li></ul>

Cigna Corporation delivered a mixed performance in the last quarter with below-par revenues but an earnings beat.Through a mix of dividends and share repurchases, Cigna returned $9 billion to shareholders.Furthermore, in Evernorth Care Services, Cigna enhanced and expanded its care management and care delivery skills portfolio.

Cigna Corporation: Proceed With Caution On This Health Services Giant – Key Drivers

<ul><li>This is our first report on Cigna Corporation, a leading player in health services and insurance.</li><li>Evernorth delivered strong top-and bottom-line results because of their innovation and affordability across pharmacy benefit services, specialty pharmacies, and Evernorth Care Solutions.</li><li>This collaboration with Centene builds on Express Scripts' reputation as a reliable partner and will eventually offer expansion options to offer more Evernorth Health services.</li></ul>

This is our first report on Cigna Corporation, a leading player in health services and insurance.Evernorth delivered strong top-and bottom-line results because of their innovation and affordability across pharmacy benefit services, specialty pharmacies, and Evernorth Care Solutions.This collaboration with Centene builds on Express Scripts' reputation as a reliable partner and will eventually offer expansion options to offer more Evernorth Health services.

Cigna Corporation: Initiation of Coverage – Business Strategy & Key Drivers

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Algosun Global

<p><a href="https://www.smartkarma.com/entities/oscar-health-inc" target="_blank" data-smartkarma-citation="entities:31499:1" rel="noopener">Oscar Health (OSCR US)</a>  stock continued to trade lower and plunged ~58% from its IPO price of $39 per share. Company will release its second quarter results after market on Thursday, August 12, 2021. Currently, Oscar Health shares trade on multiples lower than its peers, such as <a href="https://www.smartkarma.com/entities/clover-health-investments-corp" target="_blank" data-smartkarma-citation="entities:33060:1" rel="noopener">Clover Health Investments Corp (CLOV US)</a> and <a href="https://www.smartkarma.com/entities/bright-health-group-inc" target="_blank" data-smartkarma-citation="entities:33507:1" rel="noopener">Bright Health Group (BHG US)</a> . Oscar Health completed IPO in March and lock-up agreements will expire on the second trading day immediately following the public release of earnings for the second quarter. Assuming stock price of $16.20 per share, Oscar Health has enterprise value (EV) of ~$1.06 billion and ~$2.3 billion of cash, cash equivalents and marketable securities. Keeping this in mind, company has raised a total of ~$1.6 billion from American leading investment and venture capital firms. We believe that Oscar Health is M&amp;A target and may be acquired by large managed healthcare and insurance corporation.</p>

Oscar Health (OSCR US)  stock continued to trade lower and plunged ~58% from its IPO price of $39 per share. Company will release its second quarter results after market on Thursday, August 12, 2021. Currently, Oscar Health shares trade on multiples lower than its peers, such as Clover Health Investments Corp (CLOV US) and Bright Health Group (BHG US) . Oscar Health completed IPO in March and lock-up agreements will expire on the second trading day immediately following the public release of earnings for the second quarter. Assuming stock price of $16.20 per share, Oscar Health has enterprise value (EV) of ~$1.06 billion and ~$2.3 billion of cash, cash equivalents and marketable securities. Keeping this in mind, company has raised a total of ~$1.6 billion from American leading investment and venture capital firms. We believe that Oscar Health is M&amp;A target and may be acquired by large managed healthcare and insurance corporation.

Is Oscar Health M&A Target After The Shares Plunged More Than 50% Below IPO Price?

United States

The Cigna Group operates as an insurance company. The Company offers life, accident, disability, supplemental, medicare, and dental insurance products and services. The Cigna Group serves individuals, families, and businesses worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cigna Group (CI US)

The Cigna Group: How Innovation & Affordability Are Driving Impressive Growth! - Major Drivers

The Cigna Group exceeded analyst expectations in revenue and earnings, fueled by ongoing growth across its varied portfolio of companies. Cigna...

Baptista Research

The Cigna Group: Focus on Affordability and Pricing Drives Medical Cost Performance – Key Drivers

The last quarter was an all-around beat for Cigna with revenues and earnings well above Wall Street expectations. Evernorth, including pharmacy...

Baptista Research

Cigna Corporation: Proceed With Caution On This Health Services Giant – Key Drivers

Cigna Corporation delivered a mixed performance in the last quarter with below-par revenues but an earnings beat. Through a mix of dividends and...

Baptista Research

Cigna Corporation: Initiation of Coverage – Business Strategy & Key Drivers

This is our first report on Cigna Corporation, a leading player in health services and insurance. Evernorth delivered strong top-and bottom-line...

Baptista Research

Is Oscar Health M&A Target After The Shares Plunged More Than 50% Below IPO Price?

We believe that investors underestimate technology component in Oscar Health’s valuation and insurtech may be M&A target for large insurance...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)